ALUR · Allurion Technologies, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.95M | - | $2.66M | $3.38M | $5.58M | - | $5.37M | $11.77M | $9.39M | - |
| Cost of Revenue | $1.72M | - | $1.35M | $882.0K | $1.42M | - | $2.26M | $2.77M | $2.52M | - |
| Gross Profit | $1.23M | - | $1.30M | $2.50M | $4.16M | - | $3.11M | $8.99M | $6.87M | - |
| R&D | $912.0K | - | $2.02M | $1.80M | $2.62M | - | $3.21M | $4.31M | $5.72M | - |
| SG&A | $2.74M | - | $5.79M | $5.24M | $5.20M | - | $7.04M | $7.31M | $6.39M | - |
| Total Operating Expenses | $4.96M | - | $10.93M | $9.45M | $11.44M | - | $15.45M | $18.34M | $18.26M | - |
| D&A | $171.0K | - | $267.0K | $346.0K | $203.0K | - | $215.0K | $197.0K | $367.0K | - |
| Operating Income | ($3.73M) | - | ($9.63M) | ($6.95M) | ($7.28M) | - | ($12.34M) | ($9.35M) | ($11.39M) | - |
| Interest Expense | - | - | $0 | $0 | $1.93M | - | $2.59M | $339.0K | $1.93M | - |
| Income Tax | $22.0K | - | $9.0K | $43.0K | $95.0K | - | $69.0K | $65.0K | $76.0K | - |
| Net Income | ($6.09M) | - | ($11.88M) | ($9.34M) | $7.38M | - | ($9.00M) | ($2.16M) | $5.59M | - |
| EPS - Basic | ($0.46) | - | ($1.53) | ($1.28) | $1.54 | - | ($3.50) | ($1.25) | $3.00 | - |
| EPS - Diluted | ($0.46) | - | ($1.53) | ($1.28) | $0.20 | - | ($3.50) | ($1.25) | $2.75 | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $5.06M | $5.41M | $6.14M | $12.72M | $20.41M | $15.38M | $28.65M | $19.26M | $29.68M | $38.04M |
| Accounts Receivable | $3.48M | $3.95M | $3.98M | $5.85M | $8.31M | $7.13M | $9.94M | $13.36M | $16.16M | $18.19M |
| Inventory | $2.06M | $2.67M | $3.67M | $3.77M | $3.35M | $3.40M | $4.57M | $4.79M | $5.63M | $6.17M |
| Accounts Payable | $3.06M | $3.57M | $2.81M | $3.83M | $4.98M | $6.57M | $10.39M | $7.98M | $11.94M | $10.38M |
| Current Assets | $11.30M | $12.79M | $14.60M | $23.49M | $33.17M | $27.16M | $44.83M | $40.30M | $53.64M | $64.82M |
| Total Assets | $13.99M | $15.77M | $18.14M | $28.17M | $38.41M | $32.81M | $50.70M | $46.55M | $59.99M | $71.71M |
| Current Liabilities | $37.26M | $38.45M | $11.62M | $11.62M | $15.90M | $18.86M | $19.24M | $23.56M | $66.22M | $65.42M |
| Long-term Debt | $0 | - | - | $28.77M | $30.96M | $35.71M | $36.09M | $40.95M | - | - |
| Total Liabilities | $91.91M | $92.96M | $101.07M | $92.14M | $108.20M | $110.79M | $114.51M | $117.13M | $126.15M | $142.20M |
| Stockholders' Equity | ($77.91M) | ($77.19M) | ($82.93M) | ($63.98M) | ($69.79M) | ($77.98M) | ($64.79M) | ($70.58M) | ($66.16M) | ($70.49M) |
| Retained Earnings | ($257.06M) | ($250.96M) | ($244.93M) | ($233.04M) | ($231.57M) | ($238.95M) | ($218.38M) | ($209.38M) | ($207.21M) | ($212.80M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($3.22M) | - | - | - | ($9.47M) | - | - | - | ($8.64M) | - |
| Investing Cash Flow | - | - | - | - | - | - | - | - | ($104.0K) | - |
| Financing Cash Flow | $2.87M | - | - | - | $14.50M | - | - | - | $387.0K | - |
| CapEx | - | - | - | - | - | - | - | - | $104.0K | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | ($8.74M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 41.7% | - | 49.1% | 73.9% | 74.6% | - | 58.0% | 76.4% | 73.2% | - |
| Operating margin | -126.6% | - | -362.3% | -205.7% | -130.5% | - | -229.9% | -79.4% | -121.4% | - |
| EBITDA margin | -120.8% | - | -352.3% | -195.5% | -126.9% | - | -225.9% | -77.8% | -117.4% | - |
| Net margin | -206.8% | - | -447.1% | -276.3% | 132.2% | - | -167.8% | -18.4% | 59.5% | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | -93.1% | - |
| FCF / Net income | - | - | - | - | - | - | - | - | -1.56 | - |
| R&D / Revenue | 30.9% | - | 75.8% | 53.3% | 47.0% | - | 59.8% | 36.6% | 61.0% | - |
| SG&A / Revenue | 93.1% | - | 217.8% | 155.0% | 93.2% | - | 131.2% | 62.1% | 68.0% | - |
| Effective tax rate | - | - | - | - | 1.3% | - | - | - | 1.3% | - |
| Return on assets | -43.6% | - | -65.5% | -33.1% | 19.2% | - | -17.8% | -4.6% | 9.3% | - |
| Return on equity | 7.8% | - | 14.3% | 14.6% | -10.6% | - | 13.9% | 3.1% | -8.4% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 0.30 | 0.33 | 1.26 | 2.02 | 2.09 | 1.44 | 2.33 | 1.71 | 0.81 | 0.99 |
| Quick ratio | 0.25 | 0.26 | 0.94 | 1.70 | 1.88 | 1.26 | 2.09 | 1.51 | 0.72 | 0.90 |
| Cash ratio | 0.14 | 0.14 | 0.53 | 1.10 | 1.28 | 0.82 | 1.49 | 0.82 | 0.45 | 0.58 |
| Leverage | ||||||||||
| Debt / Equity | 0.00 | - | - | -0.45 | -0.44 | -0.46 | -0.56 | -0.58 | - | - |
| Debt / Assets | 0.00 | - | - | 1.02 | 0.81 | 1.09 | 0.71 | 0.88 | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | -3.8x | - | -4.8x | -27.6x | -5.9x | - |
| Equity multiplier | -0.18 | -0.20 | -0.22 | -0.44 | -0.55 | -0.42 | -0.78 | -0.66 | -0.91 | -1.02 |
| Liabilities / Assets | 6.57 | 5.89 | 5.57 | 3.27 | 2.82 | 3.38 | 2.26 | 2.52 | 2.10 | 1.98 |
| Efficiency | ||||||||||
| Asset turnover | 0.21 | - | 0.15 | 0.12 | 0.15 | - | 0.11 | 0.25 | 0.16 | - |
| Inventory turnover | 0.83 | - | 0.37 | 0.23 | 0.42 | - | 0.49 | 0.58 | 0.45 | - |
| Days sales outstanding | 430d | - | 547d | 632d | 544d | - | 676d | 414d | 628d | - |
| Days inventory outstanding | 438d | - | 988d | 1561d | 862d | - | 739d | 630d | 816d | - |
| Days payable outstanding | 651d | - | 758d | 1584d | 1280d | - | 1681d | 1051d | 1730d | - |
| Cash conversion cycle | 217d | - | 777d | 609d | 126d | - | -267d | -6d | -286d | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | 16.0x | - | - | - | 15.9x | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | 3.1x | - | 6.0x | 5.3x | 3.5x | - | 183.0x | 101.7x | 229.3x | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | -47.2% | - | -50.5% | -71.3% | -40.5% | - | -70.5% | -9.2% | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | -70.5% | - | -58.1% | -72.2% | -39.4% | - | -77.7% | -9.8% | - | - |
| Operating income growth (YoY) | 48.8% | - | 22.0% | 25.6% | 36.1% | - | 52.8% | 29.7% | - | - |
| Net income growth (YoY) | - | - | -32.0% | -331.8% | 32.1% | - | 33.7% | 90.2% | - | - |
| EPS growth (YoY) | - | - | 56.3% | -2.4% | -92.7% | - | -548.1% | 57.8% | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -11.6% | 1.0% | -28.0% | 9.4% | -5.5% | -10.6% | -221.2% | -105.9% | - | - |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Geographic
$15.23M totalAll Other Countries$11.23M · 73.8%
ES$2.15M · 14.1%
IT$1.84M · 12.1%
Peer comparison
Same SIC group: Surgical & Medical Instruments & Apparatus
Comparing ALLURION TECHNOLOGIES against the 5 most active filers in the same SIC group.